Medicine composition for preventing and treating asthma

Abstract

The invention discloses a medicine composition for preventing and treating asthma, containing active components of 1 percent by weight of inactivated mycobacterium phlei F.U.36 and 1000-2000 percent by weight of salbutamol sulfate. The medicine composition is used for treating patients suffering from mild to moderate bronchial asthma and according with the 2006GINA diagnosis standard, measuring the lung function (FEV1%, PEF%) of the patients before and after treatment and the airway reactivity (PD20-FEV1), observing the symptoms of the patients and untoward effects of medicaments, and the like, and the difference of the FEV1% and the PEF% has no statistical significance as comparison before and after the treatment; the PD20-FEV1 after the treatment is obviously increased (p is smaller than 0.01) than that before the treatment; the provocation test negative conversion ratio is 88.9% (24 cases); and after the treatment, the symptoms of the patients are obviously relieved or disappear. Results show that the medicine composition can rapidly lower the airway reactivity and relieve the symptoms of asthma.

Description

technical field [0001] The invention relates to a medicine for treating respiratory diseases such as bronchitis and asthma, which comprises a combination of inactivated mycobacterium phlei and salbutamol sulfate active ingredients. Background technique [0002] Asthma is a common disease, frequently-occurring disease, and its incidence rate is on the rise. The Global Initiative for Asthma (GINA) clearly shows that there is currently no effective cure for bronchial asthma in the world, and the main treatment method is to achieve clinical control through long-term inhalation of glucocorticoids. The data also shows that only about 70% of patients who inhale glucocorticoids according to the standard achieve clinical control (due to various reasons, in fact, most patients cannot standardize the medication for a long time, especially in primary medical institutions), and many of them stop taking the drug. Often relapse or worsen afterwards. Due to the need for long-term medicati...

AI Technical Summary

Problems solved by technology

The data also shows that only about 70% of patients who inhale glucocorticoids according to the standard achieve clinical control (due to various reasons, in fact, most patients cannot standardize the medication for a long time, especially in primary medical institutions), and many of them stop taking the drug. often relapse or worsen

The actual clinical effect and patient compliance of the GINA comprehensive prevention and control program are not ideal due to the need for long-term medication, difficult to master the use method, certain adverse reactions, high cost, and easy recurrence after drug withdrawal.

Images